Gefitinib for advanced or metastatic non-small cell lung cancer.
Gefitinib is approved as monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have failed prior platinum-based treatment and docetaxel chemotherapy. Its efficacy when compared to standard treatment and best supportive care is unproven. Common drug-related adverse effects include gastrointestinal and skin disorders. Rare but serious drug-related adverse events, such as shock, thrombophlebitis, thrombocytopenia and interstitial lung disease, have been reported.
Perras
Christine
C
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D001315:Australia; D002170:Canada; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017277:Drug Approval; D016527:Drug Costs; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D006801:Humans; D007564:Japan; D008175:Lung Neoplasms / Q000188:drug therapy*; D009367:Neoplasm Staging; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014481:United States
D000970:Antineoplastic Agents; D011799:Quinazolines; D004815:Epidermal Growth Factor; D011505:Protein-Tyrosine Kinases